Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

NCT00570700 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Hormone-refractory Prostate Cancer
Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Prostate Cancer
Recurrent Prostate Cancer

Interventions

DRUG: Dasatinib

Sponsor

University of California, Irvine

Collaborators

[object Object]